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Abstract: Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy 
of patients with myocardial infarction and heart failure due to their proven beneﬁcial effects 
in left ventricular remodeling and left ventricular function. ACE inhibitors have also been 
demonstrated to lead to regression of left ventricular hypertrophy (LVH). It is believed that 
the mechanism of action of LVH regression with ACE inhibitors arises from more than 
simple blood pressure reduction. LVH is an important risk factor for cardiovascular disease 
morbidity and mortality independent of blood pressure. Moexipril hydrochloride is a long-acting, 
non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. 
Moexipril has now also been demonstrated to have beneﬁcial effects on LVH and can lead 
to LVH regression.
Keywords: moexipril, ACE inhibitor, cardiovascular disease, left ventricular hypertropy
Background
Moexipril hydrochloride is a long acting, non-sulfhydryl angiotensin-converting 
enzyme (ACE) inhibitor that can be taken once daily for the treatment of hyperten-
sion (HTN) (White et al 1994; Stimpel et al 1995). It is a pro-drug that needs to be 
hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, in order to be 
effective (Stimpel et al 1995). Moexipril’s synthesis has been reported previously in 1982 
and 1986 (Hoeﬂe et al 1982; Klucthko et al 1986). It is incompletely absorbed after oral 
administration, and its bioavailability is low, accounting for 22% of unchanged drug. 
This is similar in comparison with other ACE inhibitors, such as benazepril, fosinopril, 
and trandolapril, which have bioavailability of 37%, 32%, and 30%, respectively. 
Cilazapril, enalapril, quinapril, and ramipril have higher bioavailability (Table 1) 
(Grass and Morehead 1986; Barfour and Gos 1995; Lancaster and Todd 1998; Singhvi 
et al 1998; Song and White 2002). 
Moexipril exerts its biological and antihypertensive effects after its metabolism 
in the liver into its active metabolite, moexiprilat, by blocking the conversion of 
angiotensin I to angiotensin II (Figure 1). Additionally, it blocks the degradation 
of bradykinin, which causes a hypotensive effect because of the potent vasodilation 
caused by the production of prostaglandin E2 and nitric oxide. Animal studies 
comparing moexipril to captopril have demonstrated equivalency in their antihyper-
tensive effects. When compared with enalapril in spontaneously hypertensive rats, 
both moexipril and enalapril reduced the mean blood pressure by 24% at 28 days 
(Edling et al 1995). In clinical studies, moexipril produced signiﬁcant reduction in 
both systolic and diastolic blood pressure with its maximum effect seen at 6 hours 
post-administration (Strauss et al 1994; Lucas et al 1995). When administered in a 
dose between 7.5 mg and 15 mg daily, the blood pressure effects have been shown 
to last 24 hours.Vascular Health and Risk Management 2007:3(1) 24
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Cardiovascular effects
Moexipril has been demonstrated in in vitro and in vivo studies 
to possess cardioprotective properties. In rats, administration of 
10 mg moexipril either alone or in combination with losartan, one 
week prior to induction of myocardial infarction, decreased the 
infarct size. These beneﬁcial effects of moexipril were negated by 
the bradykinin b2 receptor antagonist icatibant. Administration of 
losartan alone did not demonstrate any signiﬁcant effect on infarct 
size (Rosendorff 1996). Although these ﬁndings suggest that 
these beneﬁcial effects of moexipril were mediated exclusively 
through inhibition of the breakdown of bradykinin, other studies 
have shown that the cardioprotective effects of ACE inhibitors 
are mediated through a combination of inhibition of angiotensin 
II production and bradykinin degradation (Froshlich and Horinak 
1991; Brilla et al 1996; Rumble et al 1996; Grohe et al 1997; 
Chrysant 1998a). Angiotensin II exerts its remodeling effects on 
the cardiovascular system through its direct proliferative actions 
and also indirectly through its stimulation of the production of 
endothelin 1 and 3 (ET1, ET3) and the transforming growth factor 
b1 (TGF-b1), all of which have tissue proliferative effects (Figure 
2). Bradykinin itself, and through its stimulation in the production 
of prostaglandin E2 (PGE2) and nitric oxide (NO), exerts anti-
proliferative effects (Chrysant 1998a). In addition, angiotensin 
II stimulates the production of various protooncogenes, such 
as c-fos, c-jum and c-myc which all have cellular proliferative 
actions (Froshlich and Horinak 1991). The antiproliferative 
effects of moexipril have been demonstrated in vitro studies 
where moexipril inhibited the estrogen-stimulated growth of 
neonatal cardiac ﬁbroblasts in rats (Pfeffer et al 1992). It should 
be stated here that these effects of moexipril on cardiovascular   
remodeling have been demonstrated with other ACE inhibi-
tors and they appear to be a class effect (Grohe et al 1997). 
ACE inhibitors today are the standard therapy of patients 
with myocardial infarction and heart failure due to their prov-
en beneﬁcial effects in left ventricular remodeling and left 
ventricular function (SOLVD 1991; Dahlof et al 2002). 
Clinical experience with moexipril 
in hypertension
Moexipril has been extensively studied in patients with mild, 
moderate, or severe hypertension, compared with placebo and 
other antihypertensive drugs. It was also studied in ﬁxed combi-
nations with low dose hydrochlorothiazide (HTZ). Most of the 
studies were double-blind, randomized, multicenter short-term 
and a few were open label long-term studies. They were based 
on sitting diastolic blood pressure (SDBP) of 95–120 mmHg, of 
8–24 weeks’ or 2 years’ duration. In all these studies, moexipril 
was dispensed once daily due to its long elimination half-life of 
10 hours, in doses ranging from 7.5–30 mg. The results of the 
most pertinent studies are listed in Table 2.
Placebo-controlled studies
In placebo-controlled multicenter trials in Europe and the 
United States of 8–12 weeks’ duration in patients with mild 
to moderate essential hypertension (SDBP 95–114 mmHg), 
moexipril was more effective than placebo. Given in single 
daily doses of 7.5–30 mg, moexipril produced a sustained 
blood-pressure control over 24 hours and decreased the 
SDBP from 4 to 11 mmHg over placebo with a response 
rate of 48%–61% for those receiving moexipril 7.5 and 
Table 1 Pharmacokinetic characteristics of ACE inhibitors (Froshlich et al 1991; Edling et al 1995; Stimpel et al 1995)
Drug variable  Oral doseb  Absorption  Cmax  tmax  t½  Protein  Elimination 
  (mg)  (%)  (µg/L)  (h)  (h)  binding  route 
            (%)
aBenazepril  10  37  200c  1.5c  10–11  95  B+R
Captopril  100  75  800  1.0  <2  30  R
Cilazaprild  2.5  78  82  0.83  9c  NA  R
aEnalapril  10  60  30–40c  3.5c  11c  50c  R+B
aFosinopril  10  32  100c  3.0c  12c  95c  R+B
Lisinopril  10  25  38  7.0  12  10  R
aMoexipril  15  23  25c  2.0c  10c  72c  B+R
aPerindopril  8  75  12  3–7c  3–10c  60c  R+B
aQuinapril  40  60  1456c  1.38c  2  97c  R+B
aRamipril  10  60  33.6c  2.1c  2–4c  56c  R+B
aTrandolapril  2  10  2.8c  4–10c  10a  60c  B+R
aACE inhibitors existing as pro-drugs 
bThese were the doses given for the study of pharmacokinetics of the drug and do not represent necessarily, therapeutic doses. 
cparent drug 
dCilazapril is not yet marketed in the USA. 
Abbreviations: B, bile; R, renal; Cmax, maximal drug concentration; tmax, time to maximal drug concentration; NA, not available.Vascular Health and Risk Management 2007:3(1) 25
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Figure 1 Classical and alternative pathways of angiotensin II production.
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15 mg/day, vs 29% and 34% for those receiving placebo, 
respectively (Strauss et al 1994; Lucas et al 1995; Stimpel 
and Koch 1996, 1997).
Comparative studies
The antihypertensive effectiveness and safety of moexipril 
has also been compared with other antihypetensive drugs in 
patients with mild to moderately severe hypertension (SDBP 
95–114 mmHg). In comparison with HTZ 25 mg once daily, 
atenolol 25–50 mg once daily, metoprolol 100 mg once daily, 
verapamil-SR 120–240 mg once daily, nitrendipine 20 mg 
once daily, and captopril 25–50 mg twice daily, moexipril 
given in single daily doses of 7.5–15 mg was as effective 
in lowering the blood pressure as the other antihypertensive 
drugs (Dickstein et al 1994; Abernethy et al 1995; Chrysant 
et al 1995; Stimpel et al 1996a, b; White et al 1997). Vascular Health and Risk Management 2007:3(1) 26
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Add-on studies
Moexipril was also studied in patients with moderate to 
severe hypertension as add-on therapy to pre-existing drugs. 
In one study, moexipril 7.5 once daily, or verapamil-SR 180 
mg once daily, were added to pretreatment with HCTZ 25 
mg once daily if the SDBP was 100–114 mmHg inclusive 
(Chrysant and Simpel 1998). If after 4 weeks of treatment the 
SDBP was ≥90 mmHg, the dose of moexipril was increased 
to 15 mg once daily and that of verapamil-SR to 240 mg once 
daily. This resulted in further, but similar decrease of SDBP 
by week 8. Similar results were reported by other investiga-
tors when moexipril 7.5 or 15 mg once daily were added to 
HCTZ 25 mg once daily, or to nifedipine sustained release 
20 mg twice daily (Chrysant 1994; Chrysant et al 1996).
Fixed combination studies
Moexipril has been thoroughly investigated in the treatment 
of hypertension as a low-dose combination with HCTZ. In 
multi-factorial design studies, the combination of moexipril 
3.75 mg to 30 mg with HCTZ 3.125 to 50 mg were more 
efﬁcacious in lowering the blood pressure than the individual 
components alone (Chrysant 1997). In another study, 223 pa-
tients with SDBP of 95–114 mmHg and SSBP ≤200 mmHg, 
were treated with a ﬁxed very low dose combination of 
moexipril/HCTZ 3.75/6.25 mg once daily, and demonstrated 
a reduction of their SSDP/SDBP by –7.6/–7.6 mmHg com-
pared with placebo of +0.2/–3.9 mmHg (Chrysant 1998b). 
The ﬁxed combinations of HCTZ 12.5 mg with moexipril 7.5 
mg or with metoprolol 100 mg given once daily were studied 
in 140 hypertensive patients (SDBP 95–114 mmHg), for 12 
weeks (Chrysant et al 1983). In this study both combina-
tion treatments reduced the SSBP/SDBP by 17.6/12.8 and 
17.2/13.9 mmHg for the moexirpil-HCTZ and metoprolol-
HCTZ combinations, respectively (Table 2). 
Left ventricular hypertrophy (LVH)
LVH, determined by echocardiography, is a left ventricular 
mas (LVM) or LVM index (LVMI); LVM/ body surface area 
in the upper 2.5%–5.0% of the adult population (Levy et al 1988; 
Phillips and Diamond 1999). An LVMI of  ≥25 g/m2 is considered 
to be approximately at the 95th percentile. A direct and pro-
gressive relationship exists between LVM and cardiovascular 
disease (CVD) risk, including risk of coronary heart disease 
(CHD), heart failure (HF), stroke, and sudden death (Frolich et al 
1992; Devereux and Roman 1993; Haider et al 1998). Increased 
LVM has been shown to predict the risk of CV events, especially 
fatal events, independent of BP or CHD (Koren et al 1991; Ghali 
et al 1992; Levy et al 1994). Conversely, in persons with CHD, the 
relative risk of mortality is increased two-fold by LVH (Phillips 
and Diamond 1999). In the Framingham cohort, each increase in 
LVM of 50 g/m2 was associated with an increase in relative risk 
of CVD to 1.49 in men, and 1.57 in women (Levy et al 1988). 
LVH is an important risk factor for CVD morbidity and 
mortality independent of BP. The prognostic importance 
of LVH has been shown in population studies such as the 
Framingham Heart Study and the Honolulu Heart Program, 
as well as in clinical studies of patients with essential HTN, 
secondary HTN and CHD (Koren et al 1991; Ghali et al 1992; 
Levy et al 1994). LVH found on resting ECG has been associ-
ated with the highest risk of fatal CHD, conferring a relative 
risk of 11.4 in one cohort of 7682 men followed for 12 years 
(Knutsen et al 1988). In the Framingham cohort, follow-up 
was extended until a subject developed CVD, died or attended 
clinic two years later. The increased risk of CV events was 
related to baseline electrocardiogram (ECG) voltage by 
quartile (sum of R wave in lead AVL and the S wave in lead 
V3 ≥1.3 mV [25th percentile], 1.8 mV [50th percentile], 
and 2.3 mV [75th percentile]) and repolarization abnormalities 
(classiﬁed as normal, mildly abnormal [ST-T ﬂattening, isolated 
Figure 2 Tissue level stimulation and inhibition of angiotensin II.Vascular Health and Risk Management 2007:3(1) 27
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Table 2 Summary of clinical trails with moexipril
Author    Drug  Change in SDBP from  Duration 
(n = no. pts)   (mg)  baseline (mmHg)  (weeks)
Comparative studies
  Persson (n = 201)  MO 7.5 od  –8.7  8
  (1996)  MO 15 od  –10.1  8
    HCTZ 25 od  –10.5  8
  Stimpel, Oparil (n = 97)  MO 15 od  –10.0  12
  (1998)  HCTZ 25 od  –11.8  12
  Stimpel, Webera (n = 116)  MO 15 od  –10.0  8
  (1998)  ATE 50 od  –8.4  8
  Abernethy (n = 178)  MO 75–15 od  –10.0  24
  (1995)  VER-SR 180–240 od  –11.0  24
  Stimpel (n = 159)  MO 7.5–15 od  –9.8  12
  (1996a)  CAP 25–50 BID  –8.7  12
  Agabiti-Rosei (n = 93)  MO 15 od  –15.2  8
  (1999)  NIT 20 od  –13.6  8
Add-on studies
  Chrysantb (n = 147)  MO 7.5–15 od  –11.0  12
  (1995)  VER-SR 180–240 od  –12.0  12
  Dicksteinb (n = 200)  MO 3.75 od  –8.4  8
  (1994)  MO 7.5 od  –8.8  8
    MO 15 od  –8.9  8
    PL od  –4.6  8
  Perssonc (n = 203)  MO 3.75 od  –6.0  8
  (1996)  MO 7.5 od  –9.0  8
    MO 15 od  –9.0  8
    PL od  –5.0  8
Fixed combination studies
  White (n = 272)  MO 15 od  –8.0  12
  (1997)  MO 30 od  –9.7  12
    HCTZ 25 od  –8.1  12
    HCTZ 50 od  –11.0  12
    MO/HCTZ 15/25 od  –16.0  12
    MO/HCTZ 30/50 od  –17.9  12
  Chrysant (n = 223)  MO/HCTZ 3.75/6.25 od  –7.6  12
  (1998)  PL od  –3.9  12
  Stimpel (n = 140)  MO/HCTZ 7.5/12.5 od  –12.8  12
  (1997)  MET/HCTZ 100/12.5 od  –13.9  12
Open label long-term studies
  White (n = 172)  MO 7.5–15 od  –14.0  52
  (1995)  MO/HCTZ 7.5–15/25 od  –17.0  52
  White (n = 281)  MO 7.5–30 od  –14.0  52
  (1994)  MO/HCTZ 7.5–30/12.5 od  –15.0  52
aHCTZ 25 mg od was added if necessary. 
bHCTZ 25 mg background-therapy. 
cNifedipine 20 mg background-therapy. 
Abbreviations: ATE, atenolol; CAP, captopril; HCTZ, hydrochlorothiazide; MET, metoprolol; MO, moexipril; NIT, nitrendipine; VER-SR, verapamil SR.
ST depression, T-wave inversion], or severely abnormal [ST 
depression in association with inverted or biphasic T waves]). 
Persons in the highest quartile of voltage (sum of R wave in 
lead AVL and the S wave in lead V3 ≥2.3 mV) were at highest 
risk. When voltage decreased or repolarization abnormalities 
improved (in men only), risk declined and prognosis improved 
by as much as 50%. Conversely, if voltage increased serially 
over two years of follow-up, risk doubled (Levy et al 1994). 
The prevalence of ECG evidence of LVH declined from 4.5% 
to 2.5% in men and 3.6% to 1.1% in women over 38 years of 
follow-up. Mean BP reduction was greater in women than in 
men (–15/–8 mmHg vs –4/–3 mmHg) and the prevalence of Vascular Health and Risk Management 2007:3(1) 28
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severe HTN (SBP ≥160 mmHg or DBP ≥100 mmHg) declined 
to a greater extent in women than men (28% and 18.5% to 
7.7% and 9.2% respectively) over this period (Devereux 
1995). The reduction in BP, particularly in severe HTN, is 
thought to correlate with the increased use of pharmacologic 
agents over the last several decades.
In addition to LVM or LVMI, the geometric pattern 
of the hypertrophied LV has been shown to relate to CV 
events. Four geometric patterns have been described: 1) 
concentric LVH (increased LVM and increased relative 
wall thickness, RWT) 2) eccentric LVH (increased LVM 
and normal RWT); 3) concentric remodeling (normal LVM 
and increased RWT); 4) normal geometry (normal LVM 
and RWT) (Krumholz et al 1995; Verdecchia et al 1995; 
Ghali et al 1998). The pattern associated with the highest 
incidence of morbidity and mortality is concentric LVH 
(Verdecchia et al 1995, 1998). The incidence of CV events, 
in one study, was 30% in those with concentric LVH, 25% 
in those with eccentric LVH, 15% in those with concentric 
remodeling, and 9% in those with normal geometry (Koren 
et al 1991). In another study, subjects with LVH (LVMI of 
>125 g/m2) at baseline experienced a 47% lower event rate 
when LVMI was reduced to <125 g/m2 at follow-up (mean 
follow-up was 9 years) (p = 0.002) (Schlaich and Schmeider 
1998). The prognostic importance of LV geometry indepen-
dent of CHD risk factors and LVM/LVMI is controversial. 
A study of 694 hypertensive patients with normal LVMI 
(<125 g/m2) showed that concentric remodeling of the LV 
was an important predictor of CV mortality, independent of 
conventional risk factors for CHD (Verdecchia et al 1998). 
However, other studies demonstrated that when traditional 
risk factors for CHD and LVM are taken into account, the 
geometric pattern of the LV is less predictive of CV events 
(Krumholz et al 1995; Phillips and Diamond 1999). 
Pathophysiologic mechanisms for the development of LVH 
include both hemodynamic (increased BP, wall stress, and 
increasing arterial stiffness of central arteries) and non-hemody-
namic factors (genetics, activation of the sympathetic nervous 
system, and the RAAS) (Gottdiener et al 1997). LVM has 
been shown to be closely related to SBP, while RWT appears 
to be more closely related to DBP. A large body of evidence 
relates the development of LVH to increased RAAS activity, 
in particular angiotensin II. Angiotensin II has been shown to 
stimulate ﬁbroblast activity, synthesis, and release of cytokines 
and growth factors and myocardial ﬁbrosis. Aldosterone has 
been associated with an increase in collagen in the myocardium, 
leading to interstitial ﬁbrosis in ventricular tissue.
Angiotensin-converting enzyme 
inhibitors and left ventricular 
hypertrophy
Antihypertensive therapy is effective in producing regres-
sion of LVH (Liebson et al 1995; Moser and Herbert 1996; 
Schmieder et al 1996; Thurmann et al 1998). An analysis 
of six large HTN trials involving a total of 26 741 patients 
showed that long-term use of any antihypertensive medica-
tion except direct vasodilators leads to regression of LVH 
(Thurmann et al 1998). Further, a large meta-analysis of 
39 trials of diuretics, beta-blockers (BBs), calcium channel 
blockers (CCBs), and ACE inhibitors (ACEIs) in hyper-
tensive subjects showed that LVM was related to the treat-
ment-induced decline in BP, particularly SBP (p < 0.001 vs 
p = 0.08 for DBP). Reductions in LVM of 13%, 9%, 6%, and 
7% were demonstrated with ACEIs, CCBs, BBs, and diuret-
ics, respectively (Moser and Herbert 1996). Diuretics have 
been shown in several trials to be effective in reducing LVM 
(Neaton et al 1993; Moser and Herbert 1996; Schmieder et 
al 1996; Thurmann et al 1998). Results of studies that have 
examined the effects of BBs and CCBs on regression of LVH 
have been mixed, with some studies suggesting that one or 
both of these agents are not effective (Neaton et al 1993; 
Moser and Herbert 1996; Schmieder et al 1996).
Agents that interrupt the RAAS, including ACEIs and 
antiotensin II receptor blockers (ARBs), may be more 
effective than other classes of antihypertensive drugs in 
reducing LVM. Whether reduced synthesis of angiotensin II, 
with its cytokine/growth factor-stimulating effects, potentiation 
of bradykinin with resultant stimulation of NO synthesis and 
release, and/ or inhibition of aldosterone synthesis are salient 
factors in LVH reversal related to use of these drugs is a matter 
of conjecture. Further, whether, in fact, these agents effect 
reversal of LVH via mechanisms other than BP lowering is a 
matter of active debate. 
In the LVH regression substudy of the HOPE trial, the use 
of ramipril led to LVH regression in nearly 92% of patients 
(Devereux et al 2004). This effect was independent of blood 
pressure control. Consequently, the use of ramipril led to a reduc-
tion in death, MI, and stroke. Another interesting result was that 
the use of ramipril was associated with prevention of new HF.
Moexipril and left ventricular 
hypertrophy
The use of moexipril in hypertensive subjects has been dem-
onstrated to have beneﬁcial effects on LVH. In one trial of 72 Vascular Health and Risk Management 2007:3(1) 29
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patients with echocardiographic evidence of LVH (deﬁned as a 
LVMI of >111 g/m2 in men and >106 g/m2 in women), a dose of 
15 mg of moexipril daily led to a signiﬁcant decrease in LVMI. 
The average LVMI was reduced from 121 +/– 20 g/m2 to 103 
+/–17 g/m2 (p < 0.001) in a period of 24 weeks (Sayegh et al 
2005). Another more robust study, the Moexipril and REgression 
of left ventricular hypertrophy in combination therapy (MORE) 
trial, examined the effects of moexipril in 426 hypertensive pa-
tients (Spinar and Vitovec 2005). While no predeﬁned value was 
given for LVH, the baseline LVMI in this study was 149 g/m2, 
which is well above any published accepted value for LVH by 
LVMI. The presence of LVH was established by echocardiogra-
phy. Moexipril was added on to the existing therapy and titrated 
up as needed to achieve blood pressures of <140/90 mmHg. 
In this trial, BBs were used in over 50% of patients as either 
monotherapy or in combination with diuretics and/ or CCBs. 
After 6 months of follow-up, the average blood pressure was 
reduced from 161/97 mmHg to 136/82 mmHg (p < 0.0001), and 
the LVMI decreased from 149 +/– 51 g/m2 to 137 +/–47 g/m2 (p 
< 0.0001). Several interesting ﬁndings were observed. First, an 
improvement in left atrial size was demonstrated (39.81 mm vs 
39.04 mm, p = 0.002) in addition to an improvement in LV size 
and LVMI. Second, an improvement in LV diastolic function 
was demonstrated with a signiﬁcant increase in the E/A ratio 
from 0.91 to 0.94 (p < 0.0005). Third, there was a signiﬁcant 
reduction in pulse pressure (PP) from 12.5 mmHg to 9.8 mmHg 
(p < 0.01). This is an important ﬁnding due to the very well 
established link between PP and cardiovascular morbidity and 
mortality. Therefore, it appears that moexipril as added therapy 
provides beneﬁts beyond simple blood pressure lowering that 
have been demonstrated with other ACE inhibitors.
Conclusion
Moexipril is a nonsulfhydryl ACE inhibitor with prolonged 
duration of action and is suitable for once a day administration 
for the treatment of hypertension. In doses of 7.5, 15, and 30 
mg alone or in combination with other antihypertensives, such 
as HCTZ and calcium channel blockers, moexipril is effective 
for the treatment of moderate to severe hypertension. Evidence 
is also emerging that moexipril, like other ACE inhibitors, 
is effective in reducing left ventricular hypertrophy. This is 
an extremely important feature as LVH has well established 
links to cardiovascular morbidity and mortality.
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